论文部分内容阅读
表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKI)是近年来在临床中使用的一类新的小分子靶向药物,主要用于晚期非小细胞肺癌(NSCLC)的治疗,然而并非所有的NSCLC患者对TKI敏感。近期研究发现,在NSCLC治疗过程中,EGFR突变与TKI临床敏感性密切相关,通过检测肺癌EGFR突变状况可以预测TKI治疗的效果。
Epidermal growth factor receptor (EGFR) Tyrosine kinase inhibitors (TKIs) are a new class of small molecule targeted drugs that have been used clinically in recent years and are mainly used for the treatment of advanced non-small cell lung cancer (NSCLC). However, Not all NSCLC patients are TKI sensitive. Recent studies have found that EGFR mutation is closely related to the clinical sensitivity of TKI during the treatment of NSCLC. The effect of TKI therapy can be predicted by detecting the EGFR mutation in lung cancer.